Regulatory News
Click here to join our email distribution list.
Rule 2.10 Announcement
10 October 2008
London, UK; Brentwood, TN, US: 10 October 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the “Code”), confirms that as at the close of business on 9 October 2008, the Company has 342,560,165 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN Code GB0007029209.
More Information
SAYE Blocklisting
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its 1998 Savings Related Share Option Scheme:
More Information
Unapproved Share Option Scheme
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Unapproved Share Option Scheme:
More Information
Approved Blocklisting
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Approved Share Option Scheme:
More Information
Individual Blocklisting
9 October 2008
London, UK; Brentwood, TN; 9 October 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Individual Unapproved share option arrangements:
More Information
Rule 2.10 Announcement
7 October 2008
London, UK; Brentwood, TN, US: 7 October 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the “Code”), confirms that as at the close of business on 6 October 2008, the Company has 342,450,241 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN Code GB0007029209.
More Information
Total Voting Rights
2 October 2008
London, UK; Brentwood, TN; 2 October 2008 – In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information
Holding in Company
9 September 2008
London, UK; Brentwood, TN, US: 9 September 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that on 8 September 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies (“AXA”). The notification follows a change in AXA’s Indirect Voting Rights. Details of the interest notified are as follows:
More Information
6 Month Block Listing return
9 September 2008
London, UK; Brentwood, TN; 9 September 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of the block listing for its Long Term Incentive Plan and Deferred Bonus Plan:
More Information
Holding in Company
3 September 2008
London, UK; Brentwood, TN, US: 3 September 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that on 2 September 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Citigroup on behalf of Standard Life Investments Ltd. Details of the interest notified are as follows:
More Information
Total Voting Rights
2 September 2008
London, UK; Brentwood, TN; 2 September 2008 – In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information
Holding in Company
29 August 2008
London, UK; Brentwood, TN, US: 29 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that today, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Invesco Perpetual on behalf of Invesco Limited. Details of the interest notified are as follows:
More Information
Holding in Company
14 August 2008
London, UK; Brentwood, TN, US: 14 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that on 13 August 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies (“AXA”). The notification follows an increase in its Indirect Voting Rights. Details of the interest notified are as follows:
More Information
Holding in Company
14 August 2008
London, UK; Brentwood, TN, US; 14 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that, on 12 August 2008, the following notification of interest in the ordinary share capital of the Company was received today from Aviva plc.
More Information
Rule 2.10 Announcement
14 August 2008
London, UK; Brentwood, TN, US; 14 August 2008
In accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the “Code”), Protherics confirms that at the close of business on 13 August 2008, it has 342,159,034 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN code GB0007029209.
The ISIN number above corrects that cited in the Rule 2.4 announcement issued by the Company on 13 August 2008.
More Information
Block Listing Six Monthly Return
8 August 2008
London, UK; Brentwood, TN, US: 8 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of a block listing for the Company’s 6% Unsecured Convertible Loan Notes:
More Information
Holding in Company
8 August 2008
London, UK; Brentwood, TN, US; 8 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that the following notification of interest in the ordinary share capital of the Company was received today from Aviva plc.
More Information
Documents filed with the UK Listing Authority
25 July 2008
In accordance with LR 9.6.2, Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, has today forwarded for publication through the Document Viewing Facility, copies of all resolutions passed under Special business at the Company's Annual General Meeting held on 22 July 2008.
More Information
Annual Information Update
25 July 2008
In accordance with Prospectus Rule 5.2, Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, sets out below a list of the information that has been published or made available to the public during the period beginning 20 July 2007 up to and including 24 July 2008.
More Information
2008 Annual General Meeting Results
22 July 2008
London, UK; Brentwood, TN, US: 22 July 2008 - Protherics PLC (the “Company”), the international biopharmaceutical company focused on critical care and cancer, is pleased to announce that Resolutions 1 to 7 and 9 to 11 put forward at the Annual General Meeting of the Company held earlier today were passed. Since Resolution 7 was passed, Resolution 8 was withdrawn.
More Information
Interest in Shares
4 July 2008
London, UK; Brentwood, TN, US: 4 July 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that on 3 July 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies (“AXA”). The notification follows a disposal of voting rights.
More Information
Issue of Shares
4 July 2008
London, UK; Brentwood, TN, US: 4 July 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that the Company has today issued 1,741,911 ordinary shares pursuant to the MacroMed Acquisition Agreement (“Agreement”) approved by shareholders at the Company’s Extraordinary General Meeting held on 3 January 2007 and details of which were contained in the Company’s announcement dated 7 December 2006.
More Information
Total Voting Rights
2 July 2008
London, UK; Brentwood, TN; 2 July 2008 – In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information
Documents lodged with the UK Listing Authority’s Document Viewing Facility
24 June 2008
London, UK; Brentwood, TN, US: 24 June 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that the Company’s Annual Report and Financial Statements for the year ended 31 March 2008, together with a Circular to Shareholders containing the Notice of the Company’s Annual General Meeting to be held at 12.00 noon on Tuesday 22 July 2008 at the offices of Ashurst LLP, Broadwalk House, 5 Appold Street, London EC2A 2HA, have been posted to shareholders today.
More Information
Holding in Company
13 June 2008
London, UK; Brentwood, TN, US: 13 June 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that today, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from Invesco Perpetual on behalf of Perpetual Income and Growth Investment Trust. Details of the interest notified are as follows:
More Information
Directors Dealings
13 June 2008
London, UK; Brentwood, TN, US: 13 June 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces the vesting, on 12 June 2008, of a Performance Share Award (“Award”) to Saul Komisar, Director of Protherics PLC and President of Protherics Inc. under the terms of the Company’s Deferred Bonus Plan. The Award was made on 12 June 2006 and vests two years from its Date of Grant.
More Information
Director Dealings
10 June 2008
London, UK; Brentwood, TN, US; 10 June 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, Protherics PLC announces the grant, on 9 June 2008, of the following options over Ordinary Shares in Protherics (“Ordinary Shares”) to Directors and other Persons Discharging Managerial Responsibility (PDMRs) under the terms of the Protherics PLC Long Term Incentive Plan (“LTIP”):
More Information
Director Share Purchases
3 June 2008
London, UK; Brentwood, TN; 3 June 2008 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that today, in accordance with paragraph 3.1.2 of the FSA Disclosure and Transparency Rules, the Company received notification of the following dealings in the Ordinary share capital of the Company (Ordinary 2p Shares) by Directors and other Persons Discharging Managerial Responsibility (PDMRs), which took place on 3 June 2008:
More Information
Total Voting Rights
1 May 2008
London, UK; Brentwood, TN; 1 May 2008 – In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information
Total Voting Rights
1 April 2008
London, UK; Brentwood, TN; 1 April 2008 – In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information
Block Listing
5 March 2008
London, UK; Brentwood, TN, US: 6 March 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that today, application has been made to the UK Listing Authority and the London Stock Exchange for the block listing of 259,014 ordinary shares of 2p each in the Company (the “Shares”) to be admitted to trading on the Official List and to trading on London Stock Exchange’s main market. The Shares will be used to fulfil the Company’s requirement to allot shares pursuant to the exercise of options under the terms of the Company’s 2005 Long-Term Incentive Plan and 2005 Deferred Bonus Plan.
More Information
Total Voting Rights
4 March 2008
London, UK; Brentwood, TN; 4 March 2008 – In conformity with the Transparency Directive, Protherics PLC (“Protherics”), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:
More Information
Notification of Major Interest in Shares
26 February 2008
London, UK; Brentwood, TN, US: 26 February 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that, on 25 February 2008, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies (“AXA”). Details of the notification are as follows:
More Information
Block Listing Loan Notes
8 Feburary 2008
London, UK; Brentwood, TN, US: 8 February 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of a block listing for the Company’s 6% Unsecured Convertible Loan Notes:
More Information
2008 Regulatory News
2007 Regulatory News Archive